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Introduction
Simpson-Golabi-Behmel syndrome is a rare, X-linked recessive
syndrome associated with mutations in the genes encoding
glypican 3 (GPC3). The majority of cases have been described
in pediatric males, with those affected showing manifestations of
overgrowth, congenital heart defects, and increased incidence of
neoplasia. Due to the X-linked nature of this disorder,
penetrance is not well understood in female cases. Very few
cases of female presentations of Simpson-Golabi-Behmel
syndrome have been described. We present a case of GPC3
gene mutation suggestive of Simpson-Golabi-Behmel syndrome
in an adult female patient, diagnosed based on genetic testing
performed due to a diagnosis of sebaceous carcinoma.

Patient Presentation
A 65 year old female with a past medical history of hypertension and
hyperlipidemia originally presented to the dermatologist with a 0.5 cm
erythematous, fleshy papule on her right lateral eyebrow that had been
present for approximately 2 months. She reported that the lesion
occasionally bled, but denied any associated systemic symptoms or
other dermatological complaints at that time. The lesion was biopsied
and diagnosed as a sebaceous carcinoma by dermatopathology. Due
to known associated correlation with genodermatoses,
immunohistochemical staining of the biopsy specimen, a renal
ultrasound and colonoscopy were ordered. IHC staining was negative
for any microsatellite instability for MSH-2, MSH-6, MLH-1 or PMS-2
and the patient’s colonoscopy was unremarkable. Complete renal
ultrasound revealed mild prominence of the renal pelvis and
infundibulum with no significant hydronephrosis. A follow up CT was
performed of the abdomen and pelvis which showed (add in CT
findings). The patient was diagnosed with low-grade papillary urothelial
carcinoma of the right renal pelvis and subsequently underwent a right
radical nephroureterectomy. Due to evidence of malignancy in her
ureter with associated hematuria, a follow up cystoscopy was planned.
Additional evidence of low-grade papillary carcinoma of the bladder
was unfortunately found on cystoscopy. The patient was referred to a
genetic counselor due to concern for possible Muir Torre syndrome.

Results

Discussion Continued

Due to intact expression of all four mismatch repair proteins associated with
MTS, it was reassuring that the patient did not have Lynch syndrome. The Mayo
Muir-Torre syndrome risk score was calculated with our patient receiving a score
of 1 corresponding to a relatively low likelihood of having Muir-Torre/Lynch
syndrome. Due to recent history of renal cancer, our patient elected to undergo
genetic testing and the patient was referred to a genetic counselor. Upon genetic
investigation, our patient tested positive for a heterozygous mutation in the GPC3
gene c.595>T (p.Arg199*). Germline mutations for MLH1, MSH2, MSH6, PMS2
and PTEN were negative. Mutations in GPC3 are a well-established cause of
Simpson-Golabi-Behmel syndrome (SGBS).

Discussion
SGBS is a rare, X-linked overgrowth/multiple congenital abnormality syndrome first
reported by Simpson et al. in 1975.1 Thus far, only two genes have been implicated in
the development of SGBS. The first and most well established gene causing SGBS
encodes glypican-3 protein (GPC3), a glycosylphosphatidylinositol-linked cell surface
heparan sulfate proteoglycan, which maps to Xp26.2 Similarly, GPC4 is located
adjacent to GPC3 and belongs to a family of glypicans which encode heparan sulfate
proteoglycans.3 GPC3 and GPC4 are believed to play a key role in cell growth and
division in embryonic mesodermal tissues and may modulate insulin-like growth factor
2 (IGF2) action.2,3 Diagnosis guidelines have not yet been established, but previous
cases are diagnosed based on suggestive findings in a patient with a hemizygous
mutation involving GPC3 that may also involve GPC4.4 GPC3 expression has been
linked with urothelial carcinomas, especially high grade tumors.
Due to its X-linked nature, the majority of cases that have been discussed are in male
patients. The majority of cases are also detected at an early age. The characteristics
of SGBS include pre- and post-natal overgrowth, typical facies with prominent eyes
and macroglossia, macrocephaly, organomegaly, other anomalies including
diaphragmatic hernias, renal defects, gastrointestinal defects, skeletal anomalies and
an increased tumor risk with mild/moderate intellectual deficiency.1,6 SGBS is known to
be associated with an increased risk of embryonal tumors, including Wilms tumor,
hepatoblastoma, adrenal neuroblastoma, gonadoblastoma, and hepatocellular
•
7
carcinoma. To date, it is not known if other cancers are associated with mutation
GPC.
•

Females that inherit the mutation of GPC3 are generally believed to be asymptomatic
•
carriers, although there have been very few cases of female carriers with clinical
expression of SGBS. In our review, eight cases of affected females were found
described in the literature (Punnett 1994, Pilia et al 1996, Yano et al 2011, Mujezinović•
et al 2016, Shimojima et al 2016, Vaisfeld et al 2017, Schirwani et al 2018).8,2,6,9-11,3
•
Possible explanations for this phenomenon include random X-chromosome
inactivation, which may promote phenotypic manifestations of SGBS in female
•
carriers, and homozygosity/compound heterozygosity of the causal mutation.11
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Penetrance of SGBS males is 100%, while in female carriers it is unknown.7 The
previous cases described were found in infant pediatric females due to concern
for multiple congenital abnormality syndromes, either because of known SGBS
within the family or concern for another congenital abnormality syndrome. In the
first case presented by Punnett in 1994, the patient was initially diagnosed with
Beckwith-Wiedemann syndrome, which was changed to SGBS after genetic
testing revealed a balanced X;1 translocation at Xq25-27. Similarly, the case
described by Pilia et al. was due to a balanced X;16 translocation. Yano
described a female who was identified after her brothers were diagnosed with
SGBS. Vaisfeld et al., Shimojima et al., Mujezinovic et al., and Schirwani et al.
are later cases of females who have demonstrated significant features of SGBS
as pediatric patients.3 In general, mild physical findings of SGBS are seen in
female carriers, such as increased stature, extranumerary nipples, coarse facies,
abnormal hands, and midline defects.7
To the best of our knowledge, there have been no other cases of SGBS reported
to date that have presented in an adult female with sebaceous carcinoma or with
a clinical history of renal cancer. Challenges include accurate diagnosis of SGBS
in a female because of its X-linked recessive inheritance, as well as lack of
established criteria for diagnosis. Due to paucity of female cases described in the
literature, multiple questions are raised. Is this syndrome more prevalent in
females than previously recognized? Is there an association with other
malignancies than previously described that may not be elucidated until later in
life? This case points to a possible association of increased risk of cancers
including sebaceous adenocarcinoma and renal cancer with carrier status of a
mutated G3PC gene. While many questions remain unanswered, asking them
highlights the importance of awareness of this syndrome and careful examination
of those females found to be carriers.
•
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